Jongbloed Mandy, Bortolot Martina, Wee Leonard, Huijs Jarno W J, Bellezo Murillo, Vaes Rianne D W, Aboubakar Nana Frank, Hartemink Koen J, De Ruysscher Dirk K M, Hendriks Lizza E L
Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
Department of Medicine (DMED), University of Udine, Udine, Italy.
JTO Clin Res Rep. 2024 Oct 17;5(12):100740. doi: 10.1016/j.jtocrr.2024.100740. eCollection 2024 Dec.
This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (OMD) setting. Research is underway to explore the prognostic and predictive value of biological attributes of tumor tissue, circulating cells, the tumor microenvironment, and imaging findings as biomarkers of oligometastatic NSCLC. Biomarkers that help define true OMD and predict outcomes are needed for patient selection for oligometastatic treatment, and to avoid futile treatments in patients that will not benefit from locoregional treatment. Nevertheless, these biomarkers are still in the early stages of development and lack prospective validation in clinical trials. Furthermore, the absence of a clear definition of OMD contributes to a heterogeneous study population in which different types of OMD are mixed and treatment strategies are different. Multiple tissue-based, circulating, and imaging features are promising regarding their prognostic and predictive role in NSCLC, but data is still limited and might be biased owing to the inclusion of heterogeneous patient populations. Larger homogeneous and prospective series are needed to assess the prognostic and predictive role of these biomarkers. As obtaining tissue can be difficult and is invasive, the most promising tools for further evaluation are liquid biopsies and imaging-based biomarkers as these can also be used for longitudinal follow-up.
本综述讨论了寡转移性非小细胞肺癌（NSCLC）中预测性和预后性生物标志物的当前数据，并探讨了在其他阶段和广泛转移性疾病中鉴定出的生物标志物是否可外推至寡转移性疾病（OMD）情况。目前正在进行研究，以探索肿瘤组织、循环细胞、肿瘤微环境和影像学表现的生物学特性作为寡转移性NSCLC生物标志物的预后和预测价值。对于寡转移性治疗的患者选择，以及避免对无法从局部区域治疗中获益的患者进行无效治疗，需要有助于定义真正的OMD并预测预后的生物标志物。然而，这些生物标志物仍处于开发的早期阶段，缺乏在临床试验中的前瞻性验证。此外，OMD缺乏明确的定义导致研究人群异质性，其中不同类型的OMD相互混杂且治疗策略各异。多种基于组织、循环和影像学特征在NSCLC的预后和预测作用方面很有前景，但数据仍然有限，并且由于纳入了异质性患者群体可能存在偏差。需要更大规模的同质前瞻性系列研究来评估这些生物标志物的预后和预测作用。由于获取组织可能困难且具有侵入性，进一步评估最有前景的工具是液体活检和基于影像学的生物标志物，因为这些也可用于纵向随访。
